Back to School: How biopharma can reboot drug development. Access exclusive analysis here

INNO-305: Pilot trial data

In a pilot study in 8 patients, INNO-305 was safe and elicited CD8

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE